TrialNature cancer2025

Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study.

Guillaume Cartron et al.PubMed ↗Publisher ↗

No numbers read from the abstract.